New hope for Crohn's? Real-World study tests IL-23 drugs
NCT ID NCT07545317
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 3 times
Summary
This study watches how well IL-23 inhibitors work for adults with active Crohn's disease in everyday clinics. About 665 people will get treatment chosen by their doctor and be checked at 12 and 52 weeks. The main goal is to see how many reach remission (symptom-free) by week 12, while also tracking safety and other health measures.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Sixth Affiliated Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI reads scans to forecast Crohn's complications
- Can stem cell vesicles heal Crohn's fistulas?
- Can a new drug calm the Gut's overactive immune response in Crohn's?
- Can a new drug keep Crohn's disease in check?
- Can a biologic drug tame Crohn's without steroids? a large Real-World study investigates
- Can a glass of pomegranate juice tame gut inflammation?